teva pharmaceuticals usa inc v sandoz inc us patent case supreme court united states regarding copaxone court held reviewing district court resolution subsidiary factual matters made course construction patent claim federal circuit must apply clear error de novo standard case originated southern district new york sandoz sued invalidate tevas patent drug treatment multiple sclerosis markman hearing sandoz argued claim fatally indefinite failing identify three possible meanings particular claim term related molecular weight component drug interpreted district court judge held claim term definite person ordinary skill art would interpret term molecular weight mean peak average molecular weight weight molecule prevalent judge relied part expert witness testimony sandoz appealed federal circuit reviewed claim de novo standard decided claim term fatally indefinite hence patent teva appealed us supreme court